Register Now for the 8th International Conference on Alzheimer's Disease Drug Discovery
Posted on: Thursday, 2 August 2007, 09:18 CDT
The Alzheimer's Drug Discovery Foundation (ADDF) is pleased to announce that registration is now available for their 8th International Conference on Alzheimer's Disease Drug Discovery scheduled for Monday and Tuesday, October 15-16, 2007 at The Westin New York at Times Square. Interdisciplinary academic and industry scientists worldwide are welcomed to attend this two-day conference singularly focused on the development of novel drugs to prevent and treat Alzheimer's disease and related dementias.
The conference features 32 leading international experts who will present their most recent findings, as well as discuss opportunities for collaboration. Topics to be discussed include: Neuroprotection, Anti-Amyloid and Misfolding, Anti-Tangles, Immunology and Anti-Inflammation Strategies and Cognitive Enhancers. A detailed conference agenda and registration forms are available online at www.alzdiscovery.org. Registration fees vary depending upon the type of registrant and date in which payment is received. An Early Bird Rate is available until September 1. All registrations include meals, snacks, presentation materials and entrance to a networking reception on October 15. The reception is also open to attend separately for $35 per person. Early registration is recommended due to limited seating.
This conference is being made possible through generous educational grants from Forest Research Institute, Elan Pharmaceuticals, Inc., Eli Lilly and Company, Eisai Inc., Schering-Plough, Accera, Inc., Acumen Pharmaceuticals, Inc., Neurochem Inc., Pfizer, Inc. and Wyeth Pharmaceuticals. Sponsorship and exhibition opportunities are still available.
FOR DETAILS AND TO REGISTER, VISIT: www.alzdiscovery.org.
TO SPONSOR OR EXHIBIT, CONTACT: Suzanne Grossberg, sgrossberg@alzdiscovery.org
TO REQUEST A PRESS PASS OR BE A MEDIA PARTNER, CONTACT: Conference Secretariat, meetings@worldeventsforum.com
ATTENTION CALENDAR EDITORS: Please list this meeting in your publication's calendar.
About the Alzheimer's Drug Discovery Foundation (ADDF)
The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity established in 2004 to expand upon the programs initiated by the Institute for the Study of Aging (ISOA), a private foundation founded by the Lauder family in 1998. Our mission is to accelerate drug discovery research for Alzheimer's disease (AD), related dementias and cognitive aging through venture philanthropy. To date, ADDF and ISOA have awarded $28.7 million for 195 research programs and conferences worldwide. For more information, visit www.AlzDiscovery.org.
ADDF Contact: Suzanne Grossberg Director of External Affairs +1-212-901-8008 sgrossberg@alzdiscovery.org
SOURCE: Alzheimer's Drug Discovery Foundation
Source: MARKET WIRE
Related Articles
- Newly Formed American Society for Nanomedicine (ASNM) to Hold First Conference (www.amsocnanomed.org)
- Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference
- The Apache Software Foundation Opens Registration for ApacheCon US 2009
- Growth in Drug Sales of the Top 10 Pharmaceutical Companies Slowed to its Lowest Level in Years in 2008
- China Aoxing Pharmaceutical Honored to Co-Sponsor the 10th National Conference on Drug Dependence and Sino-US Symposium in Drug Abuse and HIV/HCV Co-Morbidity
- Patent Claims Allowed Covering Samaritan's Alzheimer's Memory Recovery Drug in Australia
- MPI Research Presents Annual Educational Summit - Advances in Therapeutic Discovery & Drug Development: Preclinical Cell-Based Therapy Research
- Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimer's Conference
- Alzheimer's Drug Discovery Foundation and Elan Pharmaceuticals Announce Winners of Second Annual Novel Discovery Award Program
- Pro-Pharmaceuticals to Present Corporate Update at Rodman & Renshaw Global Healthcare Conference; ''Advancing Drugs Through Nanotechnology Glycoscience'' Presentation to Be Available Via Webcast
 |
 |
User Comments (0)
RSS Feeds